Inhibition of Kidney Proximal Tubular Glucose Reabsorption Does Not Prevent against Diabetic Nephropathy in Type 1 Diabetic eNOS Knockout Mice
PLoS ONE2014Vol. 9(11), pp. e108994–e108994
Citations Over TimeTop 10% of 2014 papers
Muralikrishna Gangadharan Komala, Simon Gross, Harshini Mudaliar, Chunling Huang, Katherine Pegg, Amanda Mather, Sylvie Shen, Carol A. Pollock, Usha Panchapakesan
Abstract
Hence SGLT2 inhibition does not have renoprotective benefits independent of glucose lowering.
Related Papers
- → Following the results of the EMPA-REG OUTCOME trial with empagliflozin, is it possible to speak of a class effect?(2017)9 cited
- → Association between Empagliflozin Use and Electrocardiographic Changes(2022)7 cited
- → The Use of Empagliflozin Post Myocardial Infarction(2023)3 cited
- Próba kliniczna EMPA-REG OUTCOME z zastosowaniem empagliflozyny — nowa era w terapii cukrzycy typu 2(2018)
- → 873-P: Empagliflozin Compliance and Influencing Factors in Patients with Heart Failure and Diabetes(2023)